{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-147984","form_type":"8-K","ticker":"CGEM","cik":"0001789972","company_name":"Cullinan Therapeutics, Inc.","filed_at":"2022-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.330564+00:00","generated_at":"2026-06-25T19:02:55.242152+00:00","sec_items":["1.01","2.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Cullinan Oncology sells Cullinan Pearl to Taiho for $275M; co-develop CLN-081 in U.S.","bullets":["Taiho will acquire Cullinan Pearl for $275M upfront, plus up to $130M in regulatory milestones.","Cullinan and Taiho will co-develop and co-commercialize CLN-081 (EGFR exon20 inhibitor) in the U.S., sharing profits 50/50.","As of March 31, 2022, cash and investments were $410M; including $275M upfront, pro forma $685M.","Cash runway extended to 2026 from prior guidance of 2024, excluding potential milestones and U.S. profit share.","Acquisition expected to close in Q2 2022, subject to HSR and other customary conditions."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-147984","json":"https://secwatch.observer/filing/0001193125-22-147984.json","markdown":"https://secwatch.observer/filing/0001193125-22-147984.md","text":"https://secwatch.observer/filing/0001193125-22-147984.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789972/000119312522147984/0001193125-22-147984-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789972/000119312522147984/d303365d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T19:02:55.242152+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}